enGene Holdings Inc. (ENGN)
Oxford Ledge is still expanding full research coverage of ENGN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A genetic medicine company developing detalimogene for bladder cancer faces development risks and resource constraints typical of early-stage biotechnology.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-06-15
- 8-K Results of operations / financial condition; Costs for exit or disposal activities; Departure/election of directors or officers; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-15
- 8-K Shareholder vote results; Financial statements and exhibits 2026-06-10
- DEF 14A Proxy statement for shareholder vote 2026-05-08
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for ENGN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ENGN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.